Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Payables (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Payables for 4 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • Quarterly Payables rose 55.22% to $4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Dec 2025, up 55.22% year-over-year, with the annual reading at $4.8 million for FY2025, 55.22% up from the prior year.
  • Payables for Q4 2025 was $4.8 million at Century Therapeutics, up from $2.6 million in the prior quarter.
  • The five-year high for Payables was $9.9 million in Q1 2022, with the low at $2.6 million in Q3 2024.
  • Average Payables over 4 years is $4.2 million, with a median of $3.5 million recorded in 2023.
  • The sharpest move saw Payables tumbled 64.87% in 2023, then soared 55.22% in 2025.
  • Over 4 years, Payables stood at $5.5 million in 2022, then crashed by 49.74% to $2.7 million in 2023, then grew by 12.19% to $3.1 million in 2024, then skyrocketed by 55.22% to $4.8 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $4.8 million, $2.6 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.